Everything below concerns IGF-1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Since 2019, Schleip has been a professor of conservative and rehabilitative orthopaedics in the Department of Sport and Health Sciences at the Technical University of Munich, and a faculty member at the Diploma University of Applied Sciences. In 2023, he was appointed as a professor of health and psychology at the Diploma University of Applied Sciences.
Several studies have quantified the amounts of hallucinogenic compounds found in the fruit bodies of Psilocybe semilanceata. In 1993, Gartz reported an average of 1% psilocybin (expressed as a percentage of the dry weight of the fruit bodies), ranging from a minimum of 0.2% to a maximum of 2.37% making it one of the most potent species (but significantly less potent than panaeolus cyanescens). In an earlier analysis, Tjakko Stijve and Thom Kuyper (1985) found a high concentration in a single specimen (1.7%) in addition to a relatively high concentration of baeocystin (0.36%). Smaller specimens tend to have the highest percent concentrations of psilocybin, but the absolute amount is highest in larger mushrooms. A Finnish study assayed psilocybin concentrations in old herbarium specimens, and concluded that although psilocybin concentration decreased linearly over time, it was relatively stable. They were able to detect the chemical in specimens that were 115 years old. Michael Beug and Jeremy Bigwood, analyzing specimens from the Pacific Northwest region of the United States, reported psilocybin concentrations ranging from 0.62% to 1.28%, averaging 1.0 ±0.2%. They concluded that the species was one of the most potent, as well as the most constant in psilocybin levels. In a 1996 publication, Paul Stamets defined a "potency rating scale" based on the total content of psychoactive compounds (including psilocybin, psilocin, and baeocystin) in 12 species of Psilocybe mushrooms.
Since 2021, China has faced a property sector crisis, with decreasing house prices, shrinking of the real estate sector and bankruptcies of many property developers, partially as a result of Xi's efforts to decrease the sector's role in the Chinese economy. Xi has heavily emphasized the role of advanced manufacturing and technology development to drive China's future economic growth. Since shortly after taking office as General Secretary, Xi emphasised the use of industrial policy to increase domestic innovation and reduce reliance on foreign technology. In 2015, Xi's administration launched the Double First-Class Construction, a higher education development and sponsorship scheme intended to replace the previous programs Project 211 and Project 985. Xi's administration has promoted Made in China 2025 plan that aims to make China self-reliant in key technologies; although publicly China de-emphasised this plan due to the outbreak of a China–United States trade war, majority of its goals were considered achieved by 2024. Since the outbreak of the trade war in 2018, Xi has further pushed calls for "self-reliance", especially on technology. China's domestic spending on R&D has significantly increased, surpassing the European Union (EU) and reaching a record $564 billion in 2020. The Chinese government has supported technology companies like Huawei through grants, tax breaks, credit facilities and other assistance, enabling their rise, leading to US countermeasures.
== Utility and benefits == Most countries currently strive to implement eHealth systems for electronic management and communication of healthcare information. The primary drivers for adoption of Electronic Health Records (EHR) and supporting infrastructure include:
Sources: en.wikipedia.org
Toxicodynamics (TD) and pharmacodynamics (PD) link a therapeutic agent or toxicant, or toxin (xenobiotic)'s dosage to the features, amount, and time course of its biological action. The mechanism of action is a crucial factor in determining effect and toxicity of the drug, taking in consideration the pharmacokinetic (PK) factors. The sort and extent of altered cellular physiology will depend on the combination of the drug's presence (as established by pharmacokinetic (PK) studies) and/or its mechanism and duration of action (PD). Types of xenobiotic-target interaction can be described either by reversible, irreversible, noncompetitive, and allosteric interaction or agonist, partial agonist, antagonist, and inverse interactions. In vitro, ex vivo, or in vivo studies can be used to assess PD and TD from the molecule to the level of the entire organism. The mechanism of drug action and adverse drug reaction is either physiochemical property based and biochemical based. Adverse drugs reactions can be classified as either idiosyncratic (type B) or intrinsic (type A). Idiosyncratic toxicity is not dosage dependent and defy the mass-action relationship. Immune-mediated processes are frequently cited as the source of type B reactions. These cannot be accurately described in preclinical research or clinical trials due to their low incidence frequency. Type A reactions are dosage (concentration) dependent. Usually, this kind of side effect is an extension of an ongoing treatment.
=== Antiplatelet medications === The antiplatelet medications, aspirin and clopidogrel, are both recommended for secondary prevention of stroke after high-risk TIAs. The clopidogrel can generally be stopped after 10 to 21 days. An exception is TIAs due to blood clots originating from the heart, in which case anticoagulants are generally recommended. After TIA or minor stroke, aspirin therapy has been shown to reduce the short-term risk of recurrent stroke by 60–70%, and the long-term risk of stroke by 13%. The typical therapy may include aspirin alone, a combination of aspirin plus extended-release dipyridamole, or clopidogrel alone. Clopidogrel and aspirin have similar efficacies and side effect profiles. Clopidogrel is more expensive and has a slightly decreased risk of GI bleed. Another antiplatelet, ticlopidine, is rarely used due to increased side effects.
The body is able to substantially reduce the amount of iron it absorbs across the mucosa. It does not seem to be able to entirely shut down the iron transport process. Also, in situations where excess iron damages the intestinal lining itself (for instance, when children eat a large quantity of iron tablets produced for adult consumption), even more iron can enter the bloodstream and cause a potentially deadly syndrome of iron overload. Large amounts of free iron in the circulation will cause damage to critical cells in the liver, the heart and other metabolically active organs. Iron toxicity results when the amount of circulating iron exceeds the amount of transferrin available to bind it, but the body is able to vigorously regulate its iron uptake. Thus, iron toxicity from ingestion is usually the result of extraordinary circumstances like iron tablet over-consumption[1] rather than variations in diet. The type of acute toxicity from iron ingestion causes severe mucosal damage in the gastrointestinal tract, among other problems. Excess iron has been linked to higher rates of disease and mortality. For example, breast cancer patients with low ferroportin expression (leading to higher concentrations of intracellular iron) survive for a shorter period of time on average, while high ferroportin expression predicts 90% 10-year survival in breast cancer patients. Similarly, genetic variations in iron transporter genes known to increase serum iron levels also reduce lifespan and the average number of years spent in good health.
=== He–Hi === Clayton Heathcock (born 1936), American chemist known for his work on the synthesis of complex polycyclic natural products Alan J. Heeger (1936–2023), American chemist known for co-founding the field of conducting polymers, 2000 Nobel Prize in chemistry Jan Baptist van Helmont (1579–1644), chemist from the Spanish Netherlands known for studying the weight gain of growing plants, The founder of pneumatic chemistry Victor Henri (1872–1940), French physical chemist of Russian parents, the first to apply ideas of physical chemistry to the properties of enzymes. Dudley R.
Robert Schleip (born 1954) is a German psychologist, human biologist and author, best known for his work in the field of fascia. He serves as the director of the Fascia Research Group, a research collaboration between the University of Ulm and the Technical University of Munich. Schleip is also the founding director of the Fascia Research Society, the research director of the European Rolfing Association and vice president of the Ida P. Rolf Research Foundation. He is involved in the alternative medicine field of rolfing.
Sources: en.wikipedia.org
=== Dynamic micelles === Certain amphiphilic block copolymer micelles display a similar behavior as surfactant micelles. These are generally called dynamic micelles and are characterized by the same relaxation processes assigned to surfactant exchange and micelle scission/recombination. Although the relaxation processes are the same between the two types of micelles, the kinetics of unimer exchange are very different. While in surfactant systems the unimers leave and join the micelles through a diffusion-controlled process, for copolymers the entry rate constant is slower than a diffusion controlled process. The rate of this process was found to be a decreasing power-law of the degree of polymerization of the hydrophobic block to the power 2/3. This difference is due to the coiling of the hydrophobic block of a copolymer exiting the core of a micelle. Block copolymers which form dynamic micelles are some of the tri-block poloxamers under the right conditions.
==== Jamaica ==== "Cow cod soup" is a traditional, rustic dish in Jamaican cuisine that is considered an aphrodisiac and made with bull penis ("cod"). It is traditionally cooked with bananas and Scotch bonnet peppers in a white rum-based broth.
Gulf War veterans found evidence of a causal link between GWS and exposure to low levels of the nerve agent sarin, which was released into the air by coalition bombing of Iraqi chemical weapons facilities. Significantly, the study found an increased incidence of GWS not only among veterans who recounted hearing nerve agent alarms, but also among veterans with the RR or QR (as opposed to the QQ) forms of the PON1 gene, which produces an enzyme that deactivates organophosphates (including sarin) through hydrolysis. By contrast, GWS was inversely associated with higher levels of the type Q isozyme, which is more efficient at breaking down sarin than its type R counterpart. The authors "found that the PON1 genotype and hearing nerve agent alarms were independent and the findings robust to both measured and unmeasured confounding, supporting a mechanistic [gene–environment] interaction. ... Moreover, the change in the combined effect from one category to the next was significantly greater than the sum of the independent effects of the environmental exposure and the genotype".
Also known as mediastinal emphysema to divers, pneumomediastinum is a volume of gas inside the mediastinum, the central cavity in the chest between the lungs and surrounding the heart and central blood vessels, usually formed by gas escaping from the lungs as a result of lung rupture. Gas bubbles escaping from a ruptured lung can travel along the outside of bronchioles and blood vessels until they reach the mediastinal cavity round the heart, major blood vessels, oesophagus and trachea. Gas trapped in the mediastinum expands as the diver continues to rise. The pressure of the trapped gas may cause intense pain inside the rib cage and in the shoulders, and the gas may compress the respiratory passageways, making breathing difficult, and collapse blood vessels. Symptoms range from pain under the sternum, shock, shallow breathing, unconsciousness, respiratory failure, and associated cyanosis. The gas will usually be absorbed by the body over time, and when the symptoms are mild, no treatment may be necessary. Otherwise it may be vented through a hypodermic needle inserted into the mediastinum. Recompression is not usually indicated.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.